2-[(3-硝基苯基)甲基]异吲哚-1,3-二酮 | 21081-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-[(3-硝基苯基)甲基]异吲哚-1,3-二酮
• 英文名称: 2-(3-nitrobenzyl)isoindoline-1,3-dione
• 英文别名: 1H-Isoindole-1,3(2H)-dione, 2-[(3-nitrophenyl)methyl]-；2-[(3-nitrophenyl)methyl]isoindole-1,3-dione
• CAS: 21081-63-0
• 化学式: C₁₅H₁₀N₂O₄
• 分子量: 282.255
• InChiKey: SIMHDCASOMEHDY-UHFFFAOYSA-N

物化性质

• 熔点：
  162-163 °C
• 沸点：
  481.6±28.0 °C(Predicted)
• 密度：
  1.464±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  83.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(3-硝基苯基)甲基]异吲哚-1,3-二酮 在 肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 4-硝基苄胺
  参考文献：
  名称：

  Chemistry of synthetic receptors and functional group arrays. 7. Molecular armatures. Synthesis and structure of Troeger's base analogs derived from 4-, 2,4-, 3,4-, and 2,4,5-substituted aniline derivatives

  摘要：

  DOI：

  10.1021/jo00236a020
• 作为产物：
  描述：

  间硝基苯甲醛 在 sodium tetrahydroborate 、 氯化亚砜 、 potassium carbonate 、 三乙胺 、 sodium iodide 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 28.0h， 生成 2-[(3-硝基苯基)甲基]异吲哚-1,3-二酮
  参考文献：
  名称：

  Sonication-induced self-assembly of flexible tris(ureidobenzyl)amine: from dimeric aggregates to supramolecular gels

  摘要：

  三（脲基苄基）胺衍生物1a,b在非极性溶液和固态中形成二聚体聚集体。具体来说，元取代的三（脲）1a能够通过超声波在某些溶剂中转变为超分子凝胶。

  DOI：

  10.1039/c2cc33408a

文献信息

• Synthesis of N-Substituted phosphoramidic acid esters as “reverse” fosmidomycin analogues
  作者：Christiana M. Adeyemi、Heinrich C. Hoppe、Michelle Isaacs、Rosalyn Klein、Kevin A. Lobb、Perry T. Kaye

  DOI：10.1016/j.tet.2019.02.003

  日期：2019.4

  fosmidomycin hydroxamate moiety is reversed and the tetrahedral methylene carbon adjacent to the phosphonate moiety is replaced by a nitrogen atom bearing different benzyl groups. The resulting phosphonate esters were designed as potential antimalarial “pro-drugs”.

  从取代的苄胺开始，已经开发了一种有效的合成途径，可以合成一系列新型的“反向”磷霉素类似物。在这些类似物中，膦酰胺异羟肟酸酯部分被颠倒，与膦酸酯部分相邻的四面体亚甲基碳被带有不同苄基的氮原子取代。所得的膦酸酯被设计为潜在的抗疟“前药”。
• [EN] COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME<br/>[FR] COMPOSITIONS PERMETTANT DE FAVORISER LA TRANSLECTURE DE CODONS DE TERMINAISON PRÉMATURÉE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：THE CENTRE FOR DRUG RES AND DEV

  公开号：WO2017049409A1

  公开（公告）日：2017-03-30

  Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycoside, to treat diseases or disorders ameliorated by modulation of a premature termination codon (PTC) of an RNA molecule in a translation system. The disorder or disease may be Dystrophic epidermolysis bullosa, Batten disease, Duchenne muscular dystrophy, cancer, and spinal muscular atrophy. Ar-L-B (I)

  公开了通式(I)的化合物，它们能够促进RNA分子在翻译系统中过早终止密码子(PTC)的通读，以及它们单独或与其他化合物如氨基糖苷的组合使用，用于治疗通过调节翻译系统中RNA分子的过早终止密码子(PTC)而得到改善的疾病或失调。该疾病或失调可能是营养不良性表皮松解症、贝敦病、杜氏肌营养不良症、癌症和脊髓性肌萎缩症。Ar-L-B (I)
• Benzylphthalimides and Phenethylphthalimides with Thalidomide-Like Activity on the Production of Tumor Necrosis Factor .ALPHA..
  作者：Keizo SASAKI、Yoshihiro SHIBATA、Yuichi HASHIMOTO、Shigeo IWASAKI

  DOI：10.1248/bpb.18.1228

  日期：——

  Benzylphthalimide analogs (P1P's) and phenethylphthalimide analogs (P2P's) have been found to exhibit thalidomide-like activity on the production of tumor necrosis factor (TNF)-α by the human leukemia cell line, HL-60, stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA). Structure-activity relationships are discussed on the basis of the TNF-α production-enhancing activity. Benzylphthalimide (P1P-00) exhibited activity which is weaker than that of thalidomide, but introduction of a methyl group at the ortho-position of the benzyl moiety (P1P-10) resulted an increase to a level comparable with that of thalidomide. Phenethylphthalimide (P2P-00) is more potent than thalidomide, and its fluorinated derivative, 2-phenethyl-4, 5, 6, 7-tetrafluoro-1H-isoindole-1, 3-dione (FP2P-00), exhibited potent activity at very low concentrations.

  苄基邻苯二甲酰亚胺类化合物（P1P's）和苯乙基邻苯二甲酰亚胺类化合物（P2P's）被发现能够在通过12-O-十四酸酯磷酸酯（TPA）刺激的人类白血病细胞系HL-60中表现出类沙利度胺的活性，促进肿瘤坏死因子（TNF）-α的产生。基于TNF-α产生增强活性，讨论了结构-活性关系。苄基邻苯二甲酰亚胺（P1P-00）表现出的活性弱于沙利度胺，但在苄基的邻位引入甲基（P1P-10）后，其活性增强至与沙利度胺相当的水平。苯乙基邻苯二甲酰亚胺（P2P-00）的活性比沙利度胺更强，其氟化衍生物2-苯乙基-4, 5, 6, 7-四氟-1H-异苯并吡咯-1, 3-二酮（FP2P-00）在极低浓度下表现出强效活性。
• [EN] 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY<br/>[FR] DÉRIVÉS DE 4-PHÉNYLAMINO-PYRIMIDINE AYANT UNE ACTIVITÉ D'INHIBITION D'UNE PROTÉINE KINASE
  申请人：VICHEM CHEMIE KUTATO KFT

  公开号：WO2011077171A1

  公开（公告）日：2011-06-30

  The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula -NH-SO2-R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

  该发明涉及一般式（I）的化合物及其药用可接受的盐和溶剂化合物，其中R1为卤素、乙烯基芳基、取代芳基、杂芳基或苯并[1,3]二噁唑基团，W为式-NH-SO2-R2或杂芳基或NHR3基团，其中R3为氢或杂芳基；n为1、2、3或4。此外，本发明涉及一种含有至少一种一般式（I）的化合物和/或其药用可接受的盐或溶剂化合物的药物组合物，并用于制备用于预防和/或治疗蛋白激酶相关疾病，特别是CDK9相关疾病，如细胞增殖性疾病、传染病、疼痛、心血管疾病和炎症的药物组合物。
• 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY
  申请人：Greff Zoltán

  公开号：US20120258968A1

  公开（公告）日：2012-10-11

  The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R 1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula —NH—SO 2 —R 2 or heteroaryl group or NHR 3 group where R 3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

  本发明涉及通式（I）的化合物及其药用盐和溶剂化物，其中R1为卤素，乙烯基芳基，取代芳基，杂芳基或苯并[1,3]二噁唑基团，W为式—NH—SO2—R2或杂芳基或NHR3基团，其中R3为氢或杂芳基；n为1、2、3或4。此外，本发明还涉及含有至少一种通式（I）的化合物和/或其药用盐或溶剂化物的药物组合物，以及将它们用于制备用于预防和/或治疗蛋白激酶相关疾病，特别是CDK9相关疾病（例如细胞增殖性疾病、传染病、疼痛、心血管疾病和炎症）的药物组合物。